Title: MCM6 is a Poor Prognostic Biomarker and Promotes Progression in Breast Cancer
Authors: Zi Lei, Peng Wang, Da-qi Jia, Lei-lei Li, Yi-peng Wu, Yuan Yang, Guo-qing Pan, Taeg Kyu Kwon
Section: 3.6 MCM6 Knockdown Inhibited the Proliferation of Breast Cancer Cells
cancer: preliminary results, key challenges, and clinical potential. Expert Opinion on Investigational Drugs. 2022; 31: 495–498. [13] Rizzo A, Ricci AD, Lanotte L, Lombardi L, Di Federico A, Brandi G, et al. Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects. Expert Opinion on Investigational Drugs. 2022; 31: 557–565. [14] Zeng T, Guan Y, Li YK,WuQ, TangXJ, Zeng X, et al. The DNA replication regulator MCM6: An emerging cancer biomarker and target. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2021; 517: 92–98. [15] Zheng Y, Shi Y, Yu S, Han Y, Kang K, Xu H, et al. GTSE1, CDC20, PCNA, and MCM6 Synergistically Affect Regulations in Cell Cycle and Indicate Poor Prognosis in Liver Cancer. Analytical Cellular Pathology (Amsterdam). 2019; 2019: 1038069. [16] Issac MSM, Yousef E, Tahir MR, Gaboury LA.MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. Neoplasia (New York, N.Y.). 2019; 21: 1015–1035. [17] Cai HQ, Cheng ZJ, Zhang HP, Wang PF, Zhang Y, Hao JJ, et al. Overexpression of MCM6 predicts poor survival in patients with glioma. Human Pathology. 2018; 78: 182–187. [18] Liu YZ, Wang BS, Jiang YY, Cao J, Hao JJ, Zhang Y, et al. MCMs expression in lung cancer: implication of prognostic significance. Journal of Cancer. 2017; 8: 3641–3647. [19] Wagner SA, Oehler H, Voigt A, Dalic D, Freiwald A, Serve H, et al. ATR inhibition rewires cellular signaling networks induced by replication stress. Proteomics. 2016; 16: 402–416. [20] Noseda M, Niessen K, McLean G, Chang L, Karsan A. Notchdependent cell cycle arrest is associated with downregulation of minichromosome maintenance proteins. Circulation Research. 2005; 97: 102–104. [21] Liu M, Hu Q, Tu M, Wang X, Yang Z, Yang G, et al. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence. Journal of Experimental &Clinical Cancer Research: CR. 2018; 37: 10. [22] Kramer AA, Zimmerman JE. Assessing the calibration of mortality benchmarks in critical care: The Hosmer-Lemeshow test revisited. Critical Care Medicine. 2007; 35: 2052–2056. [23] PencinaMJ, D’Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Statistics in Medicine. 2004; 23: 2109–2123. [24] Wu Y, Qin J, Li F, Yang C, Li Z, Zhou Z, et al. USP3 promotes breast cancer cell proliferation by deubiquitinating KLF5. The Journal of Biological Chemistry. 2019; 294: 17837–17847. [25] Jia D, Li L,Wang P, Feng Q, Pan X, Lin P, et al. ZNF24 regulates the